_ _ _ _____ ___ __ __ _(_) | _(_)___ / ( _ ) / /_ ___ ___ _ __ ___ \ \ /\ / / | |/ / | |_ \ / _ \| '_ \ / __/ _ \| '_ ` _ \ \ V V /| | <| |___) | (_) | (_) | (_| (_) | | | | | | \_/\_/ |_|_|\_\_|____/ \___/ \___(_)___\___/|_| |_| |_|
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.016.162 |
Chemical and physical data | |
Formula | C10H14N2O3 |
Molar mass | 210.233 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Crotylbarbital (Mepertan, Kalipnon, Barotal), also known as crotarbital, is a barbiturate derivative developed by Eli Lilly in the 1930s. It has sedative and hypnotic effects, and was used for the treatment of insomnia until it was replaced by newer alternative drugs with fewer side effects and lower risk of overdose.